Open-Label Extension Study of Ubenimex in Patients With Pulmonary Arterial Hypertension (WHO Group 1)
Status:
Terminated
Trial end date:
2018-08-01
Target enrollment:
Participant gender:
Summary
Ubenimex is being developed for the treatment of pulmonary arterial hypertension (PAH) (World
Health Organization [WHO] Group 1) to improve exercise capacity and delay clinical worsening.
This study is a Phase 2, open-label, multicenter, extension study to evaluate long-term
safety and efficacy of ubenimex in patients with PAH (WHO Group 1) who complete Study
EIG-UBX-001 (Study EIG-UBX-001 is a Phase 2, randomized, double-blind, placebo-controlled
clinical trial) and meet the eligibility criteria for Study EIG-UBX-002. The primary
objective for this study is:
- to obtain long-term safety and tolerability data for ubenimex (150 mg administered three
times daily [TID]) in patients with PAH (WHO Group 1).